Carlos Riveros

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “3JC48-3: Novel MYC inhibition in advanced prostate cancer.”.

3JC48-3: Novel MYC inhibition in advanced prostate cancer.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.6_suppl.181

N/A

0DataRank · unranked

1 citations

Carlos Riveros, Sanjeev Shukla, Teruko Osumi, KC Balaji, Victor Chalfant

Adjuvant immunotherapy in high-risk muscle invasive urothelial carcinoma: A systematic review and meta-analysis of randomized clinical trials

Urologic Oncology Seminars and Original Investigations(2024)10.1016/j.urolonc.2024.08.003

N/A

0DataRank · unranked

4 citations

Carlos Riveros, Guru Sonpavde, Andrea B. Apolo, Aly‐Khan A. Lalani, Christopher J.D. Wallis +2 more

Postoperative outcomes in academic versus non-academic hospitals: population-based cohort study

BJS Open(2025)10.1093/bjsopen/zraf090

N/A

0DataRank · unranked

0 citations

Sanjana Ranganathan, Michael Geng, Renil S. Titus, Natalie G. Coburn, Bheeshma Ravi +9 more